Blueprint Medicines Corporation (NASDAQ:BPMC) Submits Supplementary New Drug Application For AYVAKIT™ In Advanced Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ:BPMC) has submitted a supplemental New Drug Application to the US FDA for AYVAKIT™ (avapritinib) in treating
Read more